DEFA14A: Masimo Urges Stockholders to Vote for Kiani and Chavez Amidst Proxy Battle with Politan Capital

Masimo is urging stockholders to vote for its director nominees, Joe Kiani and Christopher Chavez, at the upcoming Annual Meeting on September 19, 2024, emphasizing the importance of their vote in determining the company's future and investment value.

Summary

• Masimo is engaged in a proxy battle with Politan Capital Management, urging stockholders to vote for its nominees, Joe Kiani and Christopher Chavez.
• The company highlights Kiani's track record of innovation, including over 4,000 patent filings, and warns of potential talent loss if Politan gains control.
• Masimo cites its recent achievements, including 22% growth in healthcare revenue year-over-year, record-breaking hospital contracts, progress towards a 30% operating margin, and raised EPS guidance.
• The company criticizes Politan's nominees as inexperienced and lacking medical technology expertise, pointing to underperformance at Centene and Azenta, two prior Politan targets.
• Masimo emphasizes Kiani's role in protecting the company's IP, including wins against Apple, Medtronic, and Philips, resulting in over $1 billion in damages and royalties.
• The company highlights endorsements from medical professionals and media outlets supporting Kiani and Chavez.
• Masimo commits to separating its consumer business and expanding the Board, which will be fully declassified in 2026, in response to stockholder feedback.
• Stockholders of record as of August 12, 2024, are entitled to vote at the Annual Meeting on September 19, 2024, using the updated GOLD proxy card.
• The company has filed a revised proxy statement with the SEC and urges stockholders to read it carefully.

Sentiment

Score: 7

Explanation: The document conveys a moderately positive sentiment, emphasizing Masimo's achievements and the importance of its current leadership while also acknowledging the challenges posed by the proxy battle. The tone is assertive and confident in the company's future prospects.

Positives

• Masimo has experienced significant growth in healthcare revenue.
• The company is securing record-breaking hospital contracts.
• Masimo is progressing towards its operating margin goals.
• The company has a strong track record of innovation and IP protection.
• Masimo is responsive to stockholder feedback and committed to maximizing stockholder value.
• Masimo has doubled its non-GAAP earnings since 2017 and beat consensus earnings estimates 29 of the last 30 quarters.

Negatives

• The company is facing a proxy battle with Politan Capital Management, creating uncertainty.
• There is a potential risk of talent loss if Politan gains control.
• Politan's nominees are criticized for lacking relevant experience.
• Prior Politan targets have reportedly underperformed the S&P 500.
• The company acknowledges that stockholders may not agree with every decision the Board has made.

Risks

• Uncertainties regarding future actions by Politan Capital Management.
• Potential cost and management distraction due to the proxy battle.
• Risk of talent loss and disruption to innovation if Politan gains control.
• The forward-looking statements are subject to various risk factors outlined in Masimo's SEC filings.

Future Outlook

Masimo aims to continue increasing profitability and capitalizing on strong product demand, with a goal of doubling EPS in the next five years. The company plans to separate its consumer business and expand the Board.

Management Comments

• 'Your votes at this meeting carry significant weight and will determine who will lead Masimo and its strategy moving forward.'
• 'We are appealing to you because leadership matters and we believe the upcoming vote will determine the future value of your investment.'
• 'We have heard you and have made commitments in response to your feedback, including a plan to separate Masimos consumer business in whichever form maximizes stockholder value as well as expand the Board, which will be fully declassified in 2026.'

Industry Context

The proxy battle reflects a broader trend of activist investors seeking to influence corporate strategy and governance. The outcome of the vote could have significant implications for Masimo's future direction and its competitive position in the medical technology industry.

Comparison to Industry Standards

• The document references Centene and Azenta, two prior Politan targets, and claims they have underperformed the S&P 500 since Politan's involvement.
• The document highlights Masimo's IP wins against major players like Apple, Medtronic, and Philips, suggesting a strong competitive advantage.
• The document cites Masimo SET being used on more than 200 million patients in leading hospitals and being the primary pulse oximetry at all 10 top U.S. hospitals as ranked in the 2024 Newsweek Worlds Best Hospitals listing.

Corporate Governance

Stakeholder Impact

• The outcome of the proxy battle will significantly impact shareholders, influencing the company's strategy and value.
• Employees may be affected by potential leadership changes and the risk of talent loss.
• Patients could be impacted by changes in Masimo's innovation and product development.
• The company's relationships with hospitals and other healthcare providers could be affected by the outcome of the vote.

Next Steps

• Stockholders are urged to vote using the updated GOLD proxy card before the September 19th Annual Meeting.
• Masimo will continue to engage with stockholders and provide updates on the proxy battle.
• The company will proceed with its plans to separate the consumer business and expand the Board.

Key Dates

Keywords

Masimo, Politan Capital, Proxy Battle, Joe Kiani, Christopher Chavez, Annual Meeting, Stockholders, Director Nominees, Corporate Governance, Innovation, Medical Technology